ANAB
HealthcareAnaptysBio, Inc. · Biotechnology · $3B
What is AnaptysBio, Inc.?
AnaptysBio is a clinical-stage biotechnology company focused on developing antibody-based therapies for inflammatory diseases and immuno-oncology. Headquartered in San Diego, California, the company is building a pipeline targeting conditions driven by immune system dysregulation.
AnaptysBio discovers and develops therapeutic antibodies aimed at modulating the immune system. Its pipeline targets dermatological inflammatory diseases and broader T-cell driven conditions. The company generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical partners, including GlaxoSmithKline and Bristol-Myers Squibb, while advancing its own clinical-stage programs toward regulatory milestones.
AnaptysBio was incorporated in 2005 and is based in San Diego, California.
- Imsidolimab — an IL-36R inhibitor antibody for dermatological inflammatory diseases
- Rosnilimab — an anti-PD-1 agonist designed to suppress T-cell driven inflammation
- ANB032 — an anti-BTLA modulator antibody for lymphoid and myeloid immune cell dysregulation
- Collaboration programs advanced under agreements with GSK and Bristol-Myers Squibb
Is ANAB a Good Stock to Buy?
UQS Score rates ANAB as Below Average overall.
The Growth pillar stands out as the clearest positive signal, reflecting the pipeline's forward momentum and the potential value embedded in its clinical programs. The Risk and Quality pillars both land at Neutral, suggesting the company is neither exceptionally stable nor in acute distress by clinical-stage standards.
The Moat pillar registers as Weak — a common challenge for clinical-stage biotechs without approved products generating recurring revenue. The Valuation pillar reads as Elevated, meaning the current market price may already reflect optimistic pipeline assumptions.
See the exact pillar breakdown and full financial metrics by signing up for a Pro account at UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ANAB pay dividends?
No — AnaptysBio, Inc. does not currently pay a dividend.
AnaptysBio does not pay a dividend. As a clinical-stage company, capital is directed toward research, clinical trials, and partnership development rather than shareholder distributions. This is standard practice for pre-revenue biotechs, where reinvestment into the pipeline is the primary mechanism for building long-term value.
When does ANAB report earnings?
AnaptysBio reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, quarterly results tend to reflect collaboration revenues, research expenditures, and cash runway rather than product sales. Pipeline milestone updates and partnership developments often carry more weight for investors than traditional earnings metrics.
For the most recent quarter's results and guidance, visit AnaptysBio's investor relations page directly.
ANAB Price History
+117.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
ANAB Long-term Outlook
AnaptysBio's Growth pillar rating of Good points to meaningful pipeline optionality — particularly as its lead programs advance through clinical stages. However, the Elevated Valuation pillar suggests the market has already priced in a degree of success, leaving limited margin for setbacks. The Neutral Risk profile reflects the inherent binary nature of clinical-stage drug development, where trial outcomes can shift the fundamental picture materially.
Growth drivers
- Advancement of imsidolimab and rosnilimab through clinical milestones
- Potential milestone payments and royalties from GSK and Bristol-Myers Squibb collaborations
- Expanding addressable market in inflammatory dermatology and immuno-oncology
Key risks
- Clinical trial failure risk across multiple pipeline programs
- Elevated valuation leaves little room for pipeline disappointments
- Dependence on partner relationships and collaboration revenues ahead of product approval
ANAB vs Peers
AnaptysBio operates in a competitive clinical-stage biotech landscape alongside other inflammation-focused developers.
Galapagos is a larger European biotech with a broader pipeline spanning fibrosis, inflammation, and oncology, giving it more diversified clinical exposure than AnaptysBio.
Sionna focuses on cystic fibrosis rather than inflammation or immuno-oncology, representing a distinct therapeutic niche within the rare disease biotech space.
Trevi targets neurologically driven conditions such as chronic pruritus, overlapping with AnaptysBio's interest in itch-related inflammatory diseases but from a different mechanistic angle.
Frequently Asked Questions
What does AnaptysBio do?
AnaptysBio is a clinical-stage biotechnology company developing antibody therapies for inflammatory diseases and immuno-oncology. Its pipeline includes programs targeting dermatological conditions and broader immune dysregulation. The company also generates revenue through collaboration and licensing agreements with major pharmaceutical partners.
Does ANAB pay dividends?
No, AnaptysBio does not currently pay a dividend. As a clinical-stage biotech, the company reinvests available capital into research and clinical development. Dividend payments are uncommon for companies at this stage of development.
When does ANAB report earnings?
AnaptysBio reports on a quarterly cadence, standard for US-listed public companies. For exact reporting dates and the most recent results, check the investor relations section of AnaptysBio's official website.
Is ANAB a good stock to buy?
UQS Score rates ANAB as Below Average overall. The Growth pillar is a relative strength, while the Moat pillar is Weak and Valuation reads as Elevated. Whether it suits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to Pro members.
Is ANAB overvalued?
The UQS Valuation pillar for ANAB is rated Elevated, suggesting the current market price may reflect optimistic assumptions about pipeline success. For clinical-stage biotechs, valuation is closely tied to trial outcomes and milestone timelines rather than current revenues.
How does ANAB compare to its competitors?
Compared to peers like Galapagos, Sionna Therapeutics, and Trevi Therapeutics, AnaptysBio is differentiated by its antibody-focused platform and its specific inflammation and immuno-oncology targets. Each competitor operates in adjacent but distinct therapeutic areas. The UQS platform provides side-by-side pillar comparisons for Pro members.
What is ANAB's market cap bracket?
AnaptysBio is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but also carries greater volatility and liquidity risk compared to large- or mega-cap peers.
Who founded AnaptysBio?
AnaptysBio was incorporated in 2005, originally under the name Anaptys Biosciences, Inc., before renaming to AnaptysBio, Inc. in July 2006. Founding details are widely available through the company's public filings and corporate history disclosures.
Is ANAB a long-term quality investment?
From a long-term quality perspective, ANAB's UQS Score of Below Average reflects a mixed profile. The Growth pillar offers forward-looking potential, but the Weak Moat and Elevated Valuation pillars are factors to weigh carefully. Long-term outcomes for clinical-stage biotechs are heavily dependent on pipeline execution.
What is the main competitive advantage of AnaptysBio?
AnaptysBio's core advantage lies in its proprietary antibody discovery platform, which has enabled it to generate multiple clinical-stage candidates and attract partnerships with large pharmaceutical companies. However, the UQS Moat pillar rates this advantage as Weak, reflecting the early-stage nature of its commercial position.
What sector does ANAB belong to?
AnaptysBio operates in the Healthcare sector, specifically within clinical-stage biotechnology. The company focuses on immunology and inflammation, areas that have attracted significant industry investment due to the large unmet medical need across dermatological and systemic inflammatory conditions.
Is ANAB a growth stock or value stock?
Based on UQS pillar labels, ANAB leans toward growth — the Growth pillar is rated Good, reflecting pipeline optionality. However, the Valuation pillar is Elevated, meaning it does not screen as a value opportunity at current prices. It fits the profile of a speculative growth name in clinical-stage biotech.
Unlock Full ANAB Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare ANAB against peers on every pillar
- ✓See how Valuation and Moat scores are calculated
- ✓Get the full analyst-grade quality profile for ANAB
- ✓Track score changes as new data becomes available
Pro Analysis
ANAB — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 17, 2026 | 40.2 | 52.8 | 30.0 | 62.5 | 46.7 | 0.0 | -3.8 |
| May 14, 2026 | 44.0 | 52.8 | 30.0 | 62.5 | 71.7 | 0.0 | +3.4 |
| May 11, 2026 | 40.6 | 55.8 | 30.0 | 62.5 | 44.3 | 0.0 | +2.2 |
| May 10, 2026 | 38.4 | 47.0 | 30.0 | 62.5 | 44.3 | 0.0 | -2.2 |
| May 2, 2026 | 40.6 | 55.8 | 30.0 | 62.5 | 44.3 | 0.0 | 0.0 |
| May 1, 2026 | 40.6 | 55.9 | 30.0 | 62.5 | 44.3 | 0.0 | 0.0 |
| Apr 28, 2026 | 40.6 | 55.8 | 30.0 | 62.5 | 44.3 | 0.0 | -0.1 |
| Apr 25, 2026 | 40.7 | 56.0 | 30.0 | 62.5 | 44.3 | 0.0 | 0.0 |
| Apr 23, 2026 | 40.7 | 56.2 | 30.0 | 62.5 | 44.3 | 0.0 | -0.8 |
| Apr 22, 2026 | 41.5 | 57.2 | 30.0 | 62.5 | 44.3 | 3.9 | -0.1 |
ANAB — Pillar Breakdown
Quality
— 52.8/100 (25%)AnaptysBio, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 62.5/100 (20%)AnaptysBio, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 46.7/100 (15%)AnaptysBio, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)AnaptysBio, Inc. appears expensively valued relative to its fundamentals and growth prospects.
How many years of FCF the market cap represents.
Enterprise value multiple relative to sector median.
Moat
— 30/100 (25%)AnaptysBio, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ANAB.
Score Composition
Financial Data
More Stock Analysis
How is the ANAB UQS Score Calculated?
The UQS (Unified Quality Score) for AnaptysBio, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses AnaptysBio, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether AnaptysBio, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.